Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III International, Randomized Study of Trabectedin Plus Pegylated Liposomal Doxorubicin (PLD) Versus Carboplatin Plus PLD in Patients With Ovarian Cancer Progressing Within 6-12 Months of Last Platinum
Brief Summary: The objective of this multicentric, randomised, Phase III study is to demonstrate superiority, in terms of survival, of trabectedin and Pegylated Liposomal Doxorubicin (PLD) versus carboplatin and PLD in partially-platinum sensitive ovarian cancer patients.


Options:
A: Arm Label: Phase 3 -Active Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: AL3818, Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin (PLD), Drug: Topotecan | Arm Label: Phase 3-Control Treatment Arm; Type: OTHER; Interventions: Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin (PLD), Drug: Topotecan | Arm Label: Phase 1b: AL3818 plus carboplatin and paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: AL3818 | Arm Label: Phase 2a: AL3818 plus carboplatin and paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: AL3818 | Intervention Type: DRUG; Name: AL3818; Assigned to Arm(s): Phase 3 -Active Treatment Arm | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Phase 3 -Active Treatment Arm, Phase 3-Control Treatment Arm | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin (PLD); Assigned to Arm(s): Phase 3 -Active Treatment Arm, Phase 3-Control Treatment Arm | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Phase 3 -Active Treatment Arm, Phase 3-Control Treatment Arm | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Phase 3 -Active Treatment Arm, Phase 3-Control Treatment Arm | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Phase 1b: AL3818 plus carboplatin and paclitaxel, Phase 2a: AL3818 plus carboplatin and paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Phase 1b: AL3818 plus carboplatin and paclitaxel, Phase 2a: AL3818 plus carboplatin and paclitaxel | Intervention Type: DRUG; Name: AL3818; Assigned to Arm(s): Phase 1b: AL3818 plus carboplatin and paclitaxel, Phase 2a: AL3818 plus carboplatin and paclitaxel
B: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
C: Arm Label: Carboplatin plus PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pegylated Lipoxomal Doxorubicin (PLD) | Arm Label: Trabectedin plus PLD; Type: EXPERIMENTAL; Interventions: Drug: Pegylated Lipoxomal Doxorubicin (PLD), Drug: Trabectedin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin plus PLD | Intervention Type: DRUG; Name: Pegylated Lipoxomal Doxorubicin (PLD); Assigned to Arm(s): Carboplatin plus PLD, Trabectedin plus PLD | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): Trabectedin plus PLD
D: Arm Label: Aflibercept 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept 4.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 4.0 mg/kg | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 2.0 mg/kg

Answer: C